OCIAD1 antibody (C-Term)
Quick Overview for OCIAD1 antibody (C-Term) (ABIN500403)
Target
See all OCIAD1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- C-Term
-
Cross-Reactivity (Details)
- Species reactivity (tested):Human
-
Purification
- Peptide affinity chromatography
-
Immunogen
- OCIAD1 antibody was raised against a 16 amino acid peptide from near the carboxy terminus of human OCIAD1.
-
Isotype
- IgG
-
-
-
-
Application Notes
-
ELISA. Western blot: 1 - 2 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Concentration
- 1.0 mg/mL
-
Buffer
- PBS containing 0.02 % sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- -20 °C
-
Storage Comment
- Store the antibody (in aliquots) at -20 °C.
-
-
- OCIAD1 (OCIA Domain Containing 1 (OCIAD1))
-
Alternative Name
- OCIAD1 / OCIA
-
Background
- OCIAD1 was identified via immunoscreening of an ovarian carcinoma cDNA library from ovarian cancer patients and is expressed in multiple tissues including ovary, placenta, brain, testis, prostate, and mammary gland. Two isoforms of OCIAD1 are known to exist, the shorter isoform is restricted to the central nervous system. OCIAD1 is a transmembrane protein whose overexpression in HEY ovarian cancer cells increased lysophosphatidic acid- (LPA-)induced, but not basal level cell adhesion to extracellular matrix proteins collagen I and laminin10/11. This adhesion is not blocked by LY294002 and GF109203X, suggesting that OCIAD1 does not use protein kinase C and PI3 kinase signaling pathways to exert its effect on adhesion.Synonyms: OCIA domain-containing protein 1, Ovarian carcinoma immunoreactive antigen
-
Gene ID
- 54940
-
NCBI Accession
- NP_060300
-
UniProt
- Q9NX40
Target
-